Editor - Chiung-Yu Hung | University of Texas at San Antonio | 19364

Journal of Infectious Disease and Pathology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

Chiung-Yu Hung

Chiung-Yu Hung
Chiung-Yu Hung
Associate Professor of Research
Univesity of Texas at San Antonio
University of Texas at San Antonio


Dr. Chiung-Yu Hung received her Ph.D. degree from the University of Texas at Austin and then joined the Department of Microbiology and Immunology at Medical College of Ohio in 1997. Dr. Hung has relocated to the University of Texas at San Antonio and she was promoted to an Associate Professor of Research in 2006. Her research is focused on studies of host-pathogen interaction and development of a vaccine against coccidioidomycosis, a human respiratory fungal infection also called Valley fever. An estimated 150 000 people in the southwestern United States infected with Coccidioides annually. It is considered to be a reemerging infectious disease. Currently, her research focuses on the creation of a subunit vaccine targeted to optimize CD4+ T-cell responses against coccidioidomycosis. She has published over 50 peer-reviewed journal articles and book chapters in the medical mycology field. She is also a coinventor of two US-patented vaccines against Coccidioides infection.

Research Interest

The major goal of this project is to evaluate experimental adjuvants for improving protective efficacy of vaccine candidates against Coccidioides infection. The deliverables are to produce a multivalent vaccine that are formulated with selected, experimental adjuvants and to evaluate the protective efficacy using a humanized murine model of coccidioidomycosis.

Global Speakers in the subject

Global Experts in the subject